UNSPSC 51332104: Veralipride

This classification denotes an antipsychotic agent with the molecular formula C17H25N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S7064109UD, chemically known as n-((1-allyl-2-pyrrolidinyl)methyl)-2,3-dimethoxy-5-sulfamoylbenzamid but generally known as veralipride, which bears US NIH Compound Identifier 47979. European Medicines Agency schedules Veralipride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00037MIG.

UNSPSC 51332104 Veralipride, a Commodity code, does not align with state and local government procurement activity in the recent opportunities record. The single recent solicitation—Seminole County, Florida's IFB60459723LAS—seeks Naloxone and Safe Drug Deactivation Systems, products unrelated to Veralipride's pharmaceutical scope. State and local procurement records show no recent activity actually purchasing Veralipride under this code.

Seminole County issued an IFB on June 30, 2026 (posted date listed as Jun 30, 2026, though the opportunity notice contains inconsistent dates including a 2023 deadline of July 26) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carries an initial two-year term with a one-year renewal option, requires E-Verify compliance and drug-free workplace certification, and may be FEMA-funded. This represents the only recent state and local opportunity tagged to the code. The mismatch between the code's nominal scope and the actual procurement suggests either a classification error or dormancy in this particular Commodity category for state and local government purchasing.